Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.40
STXS's Cash to Debt is ranked higher than
58% of the 312 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.04 vs. STXS: 0.40 )
STXS' s 10-Year Cash to Debt Range
Min: 0.27   Max: 9999
Current: 0.4

0.27
9999
Equity to Asset -0.53
STXS's Equity to Asset is ranked lower than
54% of the 304 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.57 vs. STXS: -0.53 )
STXS' s 10-Year Equity to Asset Range
Min: -0.58   Max: 0.82
Current: -0.53

-0.58
0.82
F-Score: 3
Z-Score: -24.71
M-Score: -2.56
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -15.38
STXS's Operating margin (%) is ranked higher than
56% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.43 vs. STXS: -15.38 )
STXS' s 10-Year Operating margin (%) Range
Min: -113273.68   Max: -15.38
Current: -15.38

-113273.68
-15.38
Net-margin (%) -14.86
STXS's Net-margin (%) is ranked higher than
57% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.28 vs. STXS: -14.86 )
STXS' s 10-Year Net-margin (%) Range
Min: -112942.11   Max: -14.86
Current: -14.86

-112942.11
-14.86
ROA (%) -18.82
STXS's ROA (%) is ranked higher than
56% of the 313 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.93 vs. STXS: -18.82 )
STXS' s 10-Year ROA (%) Range
Min: -217.44   Max: -18.93
Current: -18.82

-217.44
-18.93
ROC (Joel Greenblatt) (%) -537.10
STXS's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 311 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.59 vs. STXS: -537.10 )
STXS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6149.14   Max: -349.08
Current: -537.1

-6149.14
-349.08
Revenue Growth (3Y)(%) -37.40
STXS's Revenue Growth (3Y)(%) is ranked lower than
52% of the 263 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. STXS: -37.40 )
STXS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 218.5
Current: -37.4

0
218.5
EBITDA Growth (3Y)(%) -76.40
STXS's EBITDA Growth (3Y)(%) is ranked lower than
51% of the 235 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. STXS: -76.40 )
STXS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -76.4   Max: 19.6
Current: -76.4

-76.4
19.6
EPS Growth (3Y)(%) -63.80
STXS's EPS Growth (3Y)(%) is ranked lower than
51% of the 229 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.10 vs. STXS: -63.80 )
STXS' s 10-Year EPS Growth (3Y)(%) Range
Min: -63.8   Max: 17.2
Current: -63.8

-63.8
17.2
» STXS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

STXS Guru Trades in

Q2 2013

STXS Guru Trades in Q2 2013

Jim Simons 48,842 sh (-16.99%)
» More
Q3 2013

STXS Guru Trades in Q3 2013

Jim Simons Sold Out
» More
Q4 2014

STXS Guru Trades in Q4 2014

Jim Simons 35,400 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with STXS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 1.20
STXS's P/S is ranked higher than
88% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.32 vs. STXS: 1.20 )
STXS' s 10-Year P/S Range
Min: 0.15   Max: 35.43
Current: 1.2

0.15
35.43
EV-to-EBIT -10.37
STXS's EV-to-EBIT is ranked higher than
57% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 36.87 vs. STXS: -10.37 )
STXS' s 10-Year EV-to-EBIT Range
Min: -12.9   Max: -1.4
Current: -10.37

-12.9
-1.4
Current Ratio 1.27
STXS's Current Ratio is ranked higher than
52% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.62 vs. STXS: 1.27 )
STXS' s 10-Year Current Ratio Range
Min: 0.83   Max: 5.62
Current: 1.27

0.83
5.62
Quick Ratio 0.89
STXS's Quick Ratio is ranked higher than
53% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.77 vs. STXS: 0.89 )
STXS' s 10-Year Quick Ratio Range
Min: 0.68   Max: 5.19
Current: 0.89

0.68
5.19
Days Inventory 261.55
STXS's Days Inventory is ranked higher than
54% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 133.28 vs. STXS: 261.55 )
STXS' s 10-Year Days Inventory Range
Min: 115.43   Max: 10772.06
Current: 261.55

115.43
10772.06
Days Sales Outstanding 67.55
STXS's Days Sales Outstanding is ranked higher than
72% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 69.74 vs. STXS: 67.55 )
STXS' s 10-Year Days Sales Outstanding Range
Min: 40.76   Max: 8375.79
Current: 67.55

40.76
8375.79

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.38
STXS's Price/Median PS Value is ranked higher than
99% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.40 vs. STXS: 0.38 )
STXS' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 4.75
Current: 0.38

0.12
4.75
Earnings Yield (Greenblatt) -9.90
STXS's Earnings Yield (Greenblatt) is ranked higher than
50% of the 304 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.20 vs. STXS: -9.90 )
STXS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -19.3   Max: 0
Current: -9.9

-19.3
0

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:RJR1.Germany,
Stereotaxis Inc was incorporated in Delaware on June 1990. The Company designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. The Niobe system is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, efficient procedures and reduced x-ray exposure. The core components of the Niobe system have received regulatory clearance in the U.S., Canada Europe, and various other countries. In addition to the Niobe system and its components, the Company also has developed the Odyssey Solution, which consolidates the multiple sources of diagnostic and imaging information found in the interventional lab into a large-screen user interface with single mouse control, which could be connected via a private network line to other interventional labs or to a remote clinical call center. The system also features a remote viewing and recording capability, called Odyssey Cinema, which simultaneously captures procedure data from multiple sources. The tool includes an archiving capability that would allow clinicians to store and replay entire procedures or segments of procedures. This information could be accessed from locations throughout the hospital local area network and over the global Odyssey network providing physicians with a tool for clinical collaboration, remote consultation and training. The Company operates mainly in the U.S., Europe and Asia and it continues to sell its products both within and outside of the U.S. It markets its products in the U.S and internationally through a direct sales force of senior sales specialists, distributors and sales agents, supported by account managers and clinical specialists that provide training, clinical support, and other services to its customers. The markets for medical devices are intensely competitive and are characterized by rapid technological advances, frequent new product introductions, evolving industry standards and price erosion. It faces competition from companies that are developing new approaches and products for use in interventional procedures, including robotic approaches that are directly competitive with its technology. It also faces competition from companies who currently market or are developing drugs, gene or cellular therapies to treat the conditions for which the Company's products are intended.
» More Articles for STXS

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: NBN, EMMS, STXS, FOE, NVTL May 21 2012 
comment on STXS Aug 20 2011 
Stereotaxis Inc. (STXS) CEO Michael P Kaminski buys 2,800 Shares Jan 04 2011 
Stereotaxis Inc. Reports Operating Results (10-Q) Nov 05 2010 
Stereotaxis Inc. (STXS) CEO Michael P Kaminski buys 2,500 Shares May 11 2010 
Stereotaxis Inc. (STXS) CFO Daniel J Johnston buys 10,000 Shares May 10 2010 
Stereotaxis Inc. Reports Operating Results (10-Q) May 07 2010 
Stereotaxis Inc. Reports Operating Results (10-Q) Nov 06 2009 
Stereotaxis Inc. (STXS) CEO Michael P Kaminski buys 1,410 Shares Sep 03 2009 
Stereotaxis Inc. Reports Operating Results (10-Q) Aug 07 2009 

More From Other Websites
STEREOTAXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a... Mar 30 2015
Stereotaxis Extends Silicon Valley Bank Credit Facility by Three Years Mar 30 2015
Stereotaxis Extends Silicon Valley Bank Credit Facility by Three Years Mar 30 2015
Florida Hospital First in U.S. to Use Stereotaxis Vdrive(R) Duo(TM) System to Control Multiple... Mar 27 2015
Florida Hospital First in U.S. to Use Stereotaxis Vdrive(R) Duo(TM) System to Control Multiple... Mar 27 2015
STEREOTAXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Mar 26 2015
STEREOTAXIS, INC. Financials Mar 21 2015
STEREOTAXIS, INC. Files SEC form 10-K, Annual Report Mar 16 2015
Stereotaxis Reports 2014 Fourth Quarter and Full Year Financial Results Feb 25 2015
Stereotaxis Inc Earnings Call scheduled for 4:30 pm ET today Feb 25 2015
STEREOTAXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... Feb 25 2015
Stereotaxis Reports 2014 Fourth Quarter and Full Year Financial Results Feb 25 2015
Q4 2014 Stereotaxis Inc Earnings Release - After Market Close Feb 25 2015
CHU de Saint-Etienne Launches Second Stereotaxis Lab Feb 18 2015
CHU de Saint-Etienne Launches Second Stereotaxis Lab Feb 18 2015
Stereotaxis to Report Fourth Quarter and Full Year 2014 Financial Results on February 25, 2015 Feb 18 2015
Stereotaxis to Report Fourth Quarter and Full Year 2014 Financial Results on February 25, 2015 Feb 18 2015
Stereotaxis and Princess Grace Hospital Share Significant New Clinical Data for Remote Magnetic... Jan 13 2015
Tucson Medical Center and Stereotaxis Bring First Vdrive(R) With V-Loop(TM) System to U.S. Jan 08 2015
Stereotaxis Surpasses 75,000 Procedures With Remote Magnetic Navigation System Jan 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK